Galmed Pharmaceutica (GLMD) Stock Price, Quote & News

Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Stu...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 693 8448

Fax: 972 3 693 8447

Website: galmedpharma.com

Address:

16 Abba Hillel Road, Ramat Gan, Israel

VolcanicTrades Aug. 9 at 9:00 AM

$SLS congrats sella bulls. You guys deserve it. Hope the story keeps getting sweeter. Here. I have a feeling $ONCO and $GLMD will be on a similar route soon. Good luck

1 · Reply

Lowlyme Aug. 8 at 12:26 AM

$GLMD LOL!!!!. Thanks!

0 · Reply

Lowlyme Aug. 7 at 9:36 PM

$GLMD Can I get at least one like? Don't want Stocktwits new algorithms to bury me! LOL Seems like that is their new game. Btw. Again. As always! GLTA. If we ever quit laughing it's all over. LM

0 · Reply

Lowlyme Aug. 7 at 9:31 PM

$GLMD Guys I've changed my mind. Maybe. A new name might cheer me up. LOL Despite my losses. Even if means Allen is going to divert trial funds for a lot of new stationary. Personally. For the record. I think Foucie. (Sp?) Looks like a saint when compared to Allen.

1 · Reply

VolcanicTrades Aug. 6 at 9:02 PM

$GLMD swing play. $ONCO swing play

0 · Reply

Mile111 Aug. 6 at 8:05 PM

$GLMD never give Up letsss goooo 💥⚡🫯🎊✈️💶🎉💯

0 · Reply

YaKnowImRight Aug. 6 at 3:17 PM

$GLMD Annual meeting shareholder vote is out. Yay or nay on the name change?

1 · Reply

Mile111 Aug. 5 at 7:19 PM

$GLMD This Allen is a Genius Take millions of Dollars for nothing 🤡the best Manipulation Guy in History 🤦💩

0 · Reply

VolcanicTrades Aug. 5 at 6:32 PM

$GLMD I wouldn’t be upset if this went back to atleast 1.70 where I first started adding….always thought it was a home run drug it seemed. Come on Allen. So many Israeli stocks squeezed this week

1 · Reply

getsometoday Aug. 5 at 5:34 PM

$GLMD one of these days this stock is going to explode it might hit .594 or even .595

0 · Reply

Galmed’s Aramchol ODF formulation shows positive results in Parkinson’s

Jul 28, 2026, 7:00 AM EDT - 12 days ago

Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market

2026-07-16T11:45:37.000Z - 24 days ago

Galmed announces development of novel LNP cardiac targeted Aramchol formulation

Jul 16, 2026, 7:30 AM EDT - 24 days ago

Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol

2026-06-22T11:27:49.000Z - 6 weeks ago

Galmed announces restructured acquisition terms for Colospan

Jun 22, 2026, 7:00 AM EDT - 6 weeks ago

Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd.

2026-06-08T12:27:05.000Z - 2 months ago

Galmed to acquire Colospan in cash and stock deal

Jun 8, 2026, 8:10 AM EDT - 2 months ago

Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market

2026-06-02T12:19:17.000Z - 2 months ago

Galmed and Tissue Dynamics’ two-drug combination targets cardiac fibrosis

2026-06-02T12:18:29.000Z - 2 months ago

Galmed and Tissue Dynamics’ two-drug combination targets cardiac fibrosis

Jun 2, 2026, 7:30 AM EDT - 2 months ago

Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis

2026-05-14T11:53:04.000Z - 3 months ago

Galmed reports results from first-in-man PK study of Aramchol Meglumine

May 14, 2026, 7:30 AM EDT - 3 months ago

Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg

2026-05-07T07:22:50.000Z - 3 months ago

Galmed partnering with Tissue Dynamics to develop cardiac fibrosis platform

May 6, 2026, 7:30 AM EDT - 3 months ago

Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics

2026-04-14T11:43:26.000Z - 4 months ago

Galmed announces research agreement with Ramot at Tel Aviv University

Apr 14, 2026, 7:30 AM EDT - 4 months ago

Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers

2026-04-09T12:36:46.000Z - 4 months ago

Why Is Galmed Pharmaceuticals Stock (GLMD) Up Today?

2026-04-09T12:02:39.000Z - 4 months ago

Galmed announces development of brain penetrating formulation of Aramchol

Apr 9, 2026, 7:30 AM EDT - 4 months ago

Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol

Mar 31, 2026, 4:15 PM EDT - 4 months ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Jan 30, 2026, 4:15 PM EST - 6 months ago

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Dec 8, 2025, 8:30 AM EST - 8 months ago

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting

2025-12-04T13:35:34.000Z - 8 months ago

Galmed granted new Use Patent related to lead compound Aramchol

Dec 4, 2025, 8:30 AM EST - 8 months ago

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

2025-12-01T13:40:19.000Z - 8 months ago

Galmed issues CEO letter to shareholders

Dec 1, 2025, 8:30 AM EST - 8 months ago

Galmed Issues CEO Letter to Shareholders

Nov 26, 2025, 8:30 AM EST - 9 months ago

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

2025-11-18T14:47:44.000Z - 9 months ago

Galmed reports ‘meaningful’ results from AM-001 study of Aramchol meglumine

Nov 18, 2025, 8:30 AM EST - 9 months ago

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine

2025-11-17T13:41:03.000Z - 9 months ago

Galmed’s Aramchol and Bayer’s Stivarga show synergistic effect in GI cancers

Nov 17, 2025, 8:30 AM EST - 9 months ago

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro

Aug 28, 2025, 8:00 AM EDT - 1 year ago

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

2025-08-25T11:35:22.000Z - 1 year ago

Galmed approves digital asset management strategy

Aug 25, 2025, 7:30 AM EDT - 1 year ago

Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value

2025-08-18T21:25:08.000Z - 1 year ago

Galmed files to sell 7.5M shares of common stock for holders

May 27, 2025, 8:00 AM EDT - 1 year ago

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

May 22, 2025, 8:00 AM EDT - 1 year ago

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

2025-05-13T12:05:15.000Z - 1 year ago

Galmed’s Aramchol shows “significant” anti-fibrotic effects in PSC models

May 6, 2025, 7:30 AM EDT - 1 year ago

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

Apr 17, 2025, 8:30 AM EDT - 1 year ago

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

Apr 15, 2025, 8:30 AM EDT - 1 year ago

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

Apr 2, 2025, 4:10 PM EDT - 1 year ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Mar 20, 2025, 8:55 AM EDT - 1 year ago

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy

Sep 25, 2024, 8:00 AM EDT - 2 years ago

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology

Sep 19, 2024, 7:00 AM EDT - 2 years ago

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

Apr 4, 2024, 5:06 PM EDT - 2 years ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

Mar 15, 2024, 9:00 AM EDT - 2 years ago

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

Nov 20, 2023, 4:32 PM EST - 2 years ago

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

Sep 26, 2023, 8:30 AM EDT - 3 years ago

Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

Jul 14, 2023, 9:30 AM EDT - 3 years ago

Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering

Jul 10, 2023, 8:00 AM EDT - 3 years ago

Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC

Jun 1, 2023, 8:00 AM EDT - 3 years ago

Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

May 9, 2023, 7:00 AM EDT - 3 years ago

Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)

Mar 29, 2023, 5:00 PM EDT - 3 years ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022

Feb 8, 2023, 8:00 AM EST - 3 years ago

Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt

Dec 14, 2022, 5:00 PM EST - 3 years ago

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

Aug 4, 2022, 8:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

Jul 7, 2022, 8:27 AM EDT - 4 years ago

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model

May 17, 2022, 8:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results

May 17, 2022, 7:30 AM EDT - 4 years ago

Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects

May 2, 2022, 7:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results

Apr 28, 2022, 7:00 AM EDT - 4 years ago

Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment

Apr 26, 2022, 8:30 AM EDT - 4 years ago

Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2

Jan 11, 2022, 7:30 AM EST - 4 years ago

Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt

Jan 10, 2022, 7:30 AM EST - 4 years ago

Galmed announces positive results of Phase 1 study of Amilo-5MER

VolcanicTrades Aug. 9 at 9:00 AM

$SLS congrats sella bulls. You guys deserve it. Hope the story keeps getting sweeter. Here. I have a feeling $ONCO and $GLMD will be on a similar route soon. Good luck

1 · Reply

Lowlyme Aug. 8 at 12:26 AM

$GLMD LOL!!!!. Thanks!

0 · Reply

Lowlyme Aug. 7 at 9:36 PM

$GLMD Can I get at least one like? Don't want Stocktwits new algorithms to bury me! LOL Seems like that is their new game. Btw. Again. As always! GLTA. If we ever quit laughing it's all over. LM

0 · Reply

Lowlyme Aug. 7 at 9:31 PM

1 · Reply

VolcanicTrades Aug. 6 at 9:02 PM

$GLMD swing play. $ONCO swing play

0 · Reply

Mile111 Aug. 6 at 8:05 PM

$GLMD never give Up letsss goooo 💥⚡🫯🎊✈️💶🎉💯

0 · Reply

YaKnowImRight Aug. 6 at 3:17 PM

$GLMD Annual meeting shareholder vote is out. Yay or nay on the name change?

1 · Reply

Mile111 Aug. 5 at 7:19 PM

$GLMD This Allen is a Genius Take millions of Dollars for nothing 🤡the best Manipulation Guy in History 🤦💩

0 · Reply

VolcanicTrades Aug. 5 at 6:32 PM

$GLMD I wouldn’t be upset if this went back to atleast 1.70 where I first started adding….always thought it was a home run drug it seemed. Come on Allen. So many Israeli stocks squeezed this week

1 · Reply

getsometoday Aug. 5 at 5:34 PM

$GLMD one of these days this stock is going to explode it might hit .594 or even .595

0 · Reply

madan_shatri Aug. 5 at 1:07 AM

$GLMD Allen needs to talk to institutions about Galmed's potential. He needs to create awareness among investors and BPs. Otherwise every news update/development will be destroyed by Shorts

0 · Reply

VolcanicTrades Aug. 3 at 10:12 PM

$GLMD lots of Israeli stocks squeezing this week….

0 · Reply

Shakattack31 Aug. 3 at 4:35 PM

$GLMD looking forward for this to lunch pump over 8$

0 · Reply

Lowlyme Aug. 3 at 11:23 AM

$GLMD I don't know about Mile's math. But I do know that I had 4,000 shares at $6.00 per share mol. Never sold a share. Now I have 200 shares mol at $O.61 mol. I'm not very good at math, but seems to me like big loss to me. (And Allen presided over it.) GLTA

0 · Reply

Mile111 Aug. 2 at 7:56 PM

$GLMD the highest price was in Juni 2018 over 3000 Dollar ☠️Allen Take millions of Dollars this motherfucker!!!!!

1 · Reply

Mile111 Aug. 2 at 12:57 PM

$GLMD this fucking Guy Allen must Go from Rest of His life in prison 💩🤮they Bring this Stock from 2000 to 0.60 Dollar !!!! What a Shit and criminal Guy Allen is Go to hellllllll and never com back 💀

1 · Reply

Lowlyme Aug. 1 at 9:40 PM

$GLMD AW. I don't seem to remember where I put your number. If you still have mine by any chance text it to me. I'll let you know next time I'm in N.C. LM Best.

0 · Reply

Mile111 Aug. 1 at 4:00 PM

$GLMD Not delisted now IS time this shit must Go over 100 Dollar 💥⚡💯🎉🫯

0 · Reply

Lowlyme Jul. 31 at 11:14 PM

$GLMD This fits the pattern. GLTA

0 · Reply

ka1954 Jul. 31 at 10:48 PM

$GLMD we are safe now until next year. hurray. "On July 30, 2026, Galmed Pharmaceuticals Ltd. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that it is eligible for an additional 180 calendar day period, or until January 25, 2027, to regain compliance with the Nasdaq’s minimum $1 bid price per share requirement. "

0 · Reply

Arrow_Investments Jul. 31 at 9:04 PM

$GLMD

0 · Reply

YaKnowImRight Jul. 31 at 8:02 PM

$GLMD Closed w/ 5.131M MC. Let's keep it above 5M!

1 · Reply

Market Cap	3.97M
Revenue (ttm)	0.00
Net Income (ttm)	-10.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	21,900
Avg Vol	924,088
Day's Range	N/A - N/A
Shares Out	6.60M
Stochastic %K	85%
Beta	0.74
Analysts	Hold
Price Target	$12.00